ep figur prior figur
revenu figur prior figur
major potenti catalyst ahead
messag main topic confer call
biomark time jakafi guidanc competit well baricitinib
resubmiss ra manag sound bullish main topic
provid detail inform note around potenti success
advantag jakafi competitor like success baricitinib approv ra
jakafi jakafi sale flat sequenti due inventori normal occur
compani note howev jakafi patient penetr
continu increas manag continu expect growth futur
number patient jakafi increas yoy recent competitor confer
manag increas guidanc long-term revenu
partial reach goal believ jakafi must success near-term trial
pivot trial acut gvhd data expect program also
compris acut gvhd chronic gvhd could potenti
increas footprint acut gvhd itacitinib pivot trial gravita read
call manag state jakafi increas guidanc mainli due
treat mf patient earlier penetr pv market patient stay longer
treatment gvhd part long-term guidanc main driver remain mf pv
competit jakafi could come fedratinib fedratinib select jak inhibitor
celgen celg though acquisit impact biomedicin evalu mf
pv jakarta trial celgen state intend submit fedratinib approv
mf sale jakafi could pressur upon approv
fedratinib import consid total appar side effect profil
fedratinib suggest jak inhibitor number off-target effect
lead diarrhea vomit dehydr addit shown block
thiamin lead thiamin defici potenti wernick encephalopathi
manag point grade thrombocytopenia fedratinib furthermor
seem unlik platelet count could differenti celgen drug jakafi
label includ patient platelet lastli push forward
combin treatment myelofibrosi put ahead competit
result epacadostat plu keytruda melanoma continu
expect nda submiss plan approv later
prepar epacadostat launch expect sg increas
reason adjust epacadostat expens sg
guid increas modestli manag emphas includ four core
compon biomark analysi rna sequenc assum detect
differenti express gene upon treatment tumor mutat burden tmb
express level tmb cutoff mutations/mb similar would
includ melanoma patient accord patient stratifi
trial accord express biomark avail up-front
three biomark read may also depend collabor
merck furthermor manag highlight differ baselin
characterist expect compar previou trial keynot
manag emphas monotherapi
market leader melanoma patient share opdivo plu yervoy
look term safeti toler point earlier howev
would expect keytruda plu epcadostat closer opdivo plu yervoy term
efficaci progress free surviv month keytruda monotherapi
progress free surviv month taken togeth manag sound
bullish outcom
page analyst certif import disclosur
baricitinib launch uptak olumi baricitinb germani strong
compar histor humira rheumatoid arthriti believ launch trajectori
could repeat howev may depend black box warn
pertain thromboembol fda advisori committe meet baricitinib
expect manag timelin remain unknown accord
manag advisori committe expect discuss safeti problem beyond
deep vein thrombosi believ likelihood black box warn low
remind german label contain warn deep vein thrombosi emphas
highlight among warn furthermor german label also contain
dose manag state major patient use
dose call manag provid background inform clinic trial
death two report death patient pulmonari embol
clinic trial program one death occur baricitinib group day
first dose one death occur methotrex group day methotrex
treatment resubmit data packag contain clinic trial extens studi
found dose incid dvt pe
well accord manag incid well within rang
background rate ra part resubmiss one key element
abil submit much larger dataset includ longer follow-up
ph studi use market data particularli european market like
germani final registri data data culmin twice amount exposur
compound origin submiss includ mg
mg dose lilli clear new safeti signal seen larg data
set overal believ label resembl german label expect
car-t comment manag express interest io portfolio might
help augment car-t therapi singl import mechan
preclin work dlbcl show axi infgamma
expans autolog car-t cell seem interest collabor
provid comment find comment highli interest believ
disrupt potenti car-t io sphere particular allogen car-t
 spend increas spend guidanc mostli due late stage
portfolio epacadostat itacitinib gvhd co-fund baricitinib
trial ad system lupu earlier stage candid gitr
anticip taken larg scale clinic trial
made adjust model base perform guidanc
provid compani manag commentari earn call note
compani provid non-gaap reconcili beyond thu model
non-gaap estim non-gaap total revenu cog sg ebit net
incom ep model due updat guidanc slightli increas
sale estim jakafi iclusig continu expect strong jakafi growth
uptak remain strong addit made chang cog oper
expens estim base guidanc provid call base long-term
effect tax rate guidanc non- made adjust
tax rate beyond also account increas share count
occur fourth quarter subsequ year adjust
non- ep estim come previous basi
non- net revenu previous basi
valuat risk
valuat assum growth current jakafi sale ex-u royalti
myelofibrosi polycythemia vera baricitinib sale ra risk-adjust
epacadostat sale melanoma risk-adjust nsclc risk-adjust rcc
risk-adjust bladder cancer risk-adjust squamou cell head neck
cancer risk-adjust well iclusig sale take sum discount cash
flow carri use unchang risk-fre rate termin growth rate
market premium wacc plu net cash arriv pt
risk near-term risk rate price target includ limit
inci failur execut commerci jakafi unit state lower
expect ex-u jakafi royalti payment longer term key risk includ
page analyst certif import disclosur
unfavor clinical/regulatori outcom jakafi pancreat cancer baricitinib
delay approv epacadostat plu keytruda melanoma
page analyst certif import disclosur
thousand except per-shar figur
licens royalti revenu
good sold
research develop
sell gener administr
incom loss oper
incom loss oper
royal taken product royalti revenu line
page analyst certif import disclosur
